We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $875B
1-Year Est. Return 40.91%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TCRT icon
12326
PUT
Alaunos Therapeutics
TCRT
$4.71M
$19K ﹤0.01%
101
+14
+16% +$1.34K
VIVO
12327
CALL
VivoPower PLC
VIVO
$150M
$19K ﹤0.01%
1,340
-1,050
-44% -$15.7K
AAU
12328
DELISTED
Almaden Minerals Ltd
AAU
$19K ﹤0.01%
86,571
+30,627
+55% +$8.81K
GOEV
12329
DELISTED
Canoo Inc. Class A Common Stock
GOEV
$19K ﹤0.01%
22
-66
-75% -$116K
VRPX
12330
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
$19K ﹤0.01%
+46
New +$18.9K
ONCT
12331
PUT
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$19K ﹤0.01%
855
-450
-34% -$10K
CYTO
12332
CALL
DELISTED
Altamira Therapeutics Ltd
CYTO
$19K ﹤0.01%
100
-151
-60% -$48.7K
ZYNE
12333
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$19K ﹤0.01%
16,600
-1,600
-9% -$2.04K
NAVB
12334
CALL
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$19K ﹤0.01%
26,200
+11,500
+78% +$9.77K
CRVS icon
12335
PUT
Corvus Pharmaceuticals
CRVS
$1.25B
$18K ﹤0.01%
17,700
-7,300
-29% -$8.95K
FOA icon
12336
Finance of America Companies
FOA
$201M
$18K ﹤0.01%
+1,176
New +$27.2K
MSGM icon
12337
Motorsport Games
MSGM
$18.5M
$18K ﹤0.01%
+2,782
New +$23.2K
PLUR icon
12338
PUT
Pluri
PLUR
$17.3M
$18K ﹤0.01%
1,813
-600
-25% -$7.38K
RVPH
12339
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$18K ﹤0.01%
820
+105
+15% +$3.68K
TGB
12340
PUT
Trekor Metals
TGB
$3.06B
$18K ﹤0.01%
+17,100
New +$29.2K
YARW
12341
CALL
Yarrow Bioscience
YARW
$113M
$18K ﹤0.01%
51
-66
-56% -$27.7K
DVLT
12342
PUT
Datavault AI
DVLT
$272M
$18K ﹤0.01%
2
-2
-50% -$26.2K
AEON.WS
12343
DELISTED
AEON Biopharma Inc
AEON.WS
$18K ﹤0.01%
120,586
-173,015
-59% -$36.4K
HHLA.WS
12344
DELISTED
HH&L Acquisition Co. Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50
HHLA.WS
$18K ﹤0.01%
104,597
-2,946
-3% -$579
CZOO
12345
PUT
DELISTED
Cazoo Group Ltd
CZOO
$18K ﹤0.01%
12
-44
-79% -$145K
RVLP
12346
CALL
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$18K ﹤0.01%
13,100
-1,800
-12% -$2.61K
IPVIW
12347
DELISTED
InterPrivate IV InfraTech Partners Inc. Warrant
IPVIW
$18K ﹤0.01%
72,504
-2,559
-3% -$945
DTEA
12348
DELISTED
DAVIDsTEA Inc. Common Stock
DTEA
$18K ﹤0.01%
+10,608
New +$23.1K
GET
12349
DELISTED
Getnet Adquirencia e Servicos para Meios de Pagamento S.A. American Depositary Shares
GET
$18K ﹤0.01%
11,349
-15,327
-57% -$24.3K
IVC
12350
PUT
DELISTED
Invacare Corporation
IVC
$18K ﹤0.01%
14,000
-2,300
-14% -$3.03K

Similar funds

Citadel Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Citadel Advisors held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Citadel Advisors's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Citadel Advisors's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Citadel Advisors added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Citadel Advisors's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Citadel Advisors fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Citadel Advisors's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Citadel Advisors opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Citadel Advisors's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.